TTM Technologies (TTMI) Announces Proposed $500M Offering of Senior Notes Due 2029
- Wall St set to open higher after bumper earnings from big banks
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Dollar heads for second week of losses as yields decline
- Morgan Stanley (MS) Tops Q1 EPS by 52c
- Apple (AAPL) May Scrap iPhone Mini Next Year, New Lineup to Focus on Camera Quality, Says Top Analyst
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
TTM Technologies, Inc. (NASDAQ: TTMI) ("TTM") announced today that it intends to offer, subject to market and other customary conditions, $500 million in aggregate principal amount of senior notes due 2029 (the “Notes”) in a private offering exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be senior unsecured obligations of TTM and will be guaranteed by TTM’s subsidiaries that guarantee its obligations under its term loan due September 2024 and its U.S. asset-based revolving credit facility (the “U.S. ABL Facility”), subject to certain exceptions.
TTM intends to use the net proceeds from the offering of the Notes to (i) purchase any and all of TTM’s outstanding $375 million aggregate principal amount of 5.625% Senior Notes due 2025 (the “Existing Notes”) that are validly tendered and accepted for payment pursuant to TTM’s previously announced cash tender offer for any and all of the Existing Notes (the “Tender Offer”), (ii) redeem in full any remaining Existing Notes following the consummation or termination of the Tender Offer, (iii) repay the full amount outstanding under the U.S. ABL Facility (but not terminate the commitments thereunder) and (iv) pay related premiums, fees and expenses.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AAR Corp. (AIR) Reports Election of Ellen M. Lord to Board
- Audioeye (AEYE) Announces DealerCenter Selects it as Digital Accessibility Partner
- Lilly (LLY) requests revocation of EUA for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.